Unique product-level analysis for improving brand health and clinician satisfaction in the US
Clinicians treating asthma/COPD have a number of effective therapy options, but not all make the same choices. What drives clinician prescribing and decision making and why are some more loyal to certain brands than others?
This and other key questions are answered in this insightful April 2019 Net Promoter Score®1 (NPS) analysis of 9 leading asthma/COPD brands. Based on the results of an in depth survey of 100 US-based allergists and pulmonologists, NPS+ (US) Asthma/COPD Inhalables identifies the drivers that build clinician satisfaction and brand loyalty.
Leading brands covered in this report
This NPS analysis answers important brand questions
FirstView NPS+ takes you deeper than the standard NPS analysis
Since its introduction in 2003, the Net Promoter Score system has become established as a key metric for assessing user satisfaction and loyalty to brands. But while NPS helps you measure overall brand health, it doesn't tell you how to improve it. NPS+ adds much needed detail and gives you deep insights into:
Exclusive to FirstView and not available elsewhere, NPS+ does more than measure your brand’s overall health—it shows you what drives brand satisfaction so you can take action to improve physician engagement and use.
About the Allergists and Pulmonologists surveyed
This detailed analysis—based on a survey of 100 US allergists and pulmonologists who play an active role in writing prescriptions for their asthma/COPD patients—establishes which therapies they use and the clinical characteristics that influence their choices.
This report gives you...
What are Net Promoter Scores?
NPS measures overall brand satisfaction and loyalty by asking one simple question:
"How likely are you to recommend this brand to a colleague?"
Responses, given on a scale of 0 to 10, are used to classify doctors into 3 categories:
Why FirstView has an edge in pharmaceutical market research
FirstView research draws on LiMA (Leaders in Medicine Atlas), the world's largest directory of 3.5 million vetted and verified physicians. This proprietary physician research platform uses advanced big data capture, processing and analytics powered by AI and machine learning to ensure the most robust samples are used for every FirstView survey.
Other Asthma/COPD reports available
NPS+ Asthma/COPD Inhalables Europe
Medical Affairs Reputations US: Asthma/COPD Inhalables
Medical Affairs Reputations Europe: Asthma/COPD Inhalables
Market Access Impact US: Asthma/COPD Inhalables
Market Access Impact Europe: Asthma/COPD Inhalables
Targeted Therapies in Asthma: KOL Insight
COPD: KOL Insight
To learn about our cost effective Asthma/COPD Inhalables intelligence package of all reports, please contact us at info@fwreports.com
1NPS is a customer loyalty metric developed by (and a registered trademark of) Fred Reichheld, Bain & Company, and Satmetrix.
All Contents Copyright © 2021 Doctor's Guide Publishing Limited All Rights Reserved